Brain Behav:缺血性卒中后期肌张力和收缩性增加

2020-04-06 MedSci原创 MedSci原创

在没有选择的情况下,关于缺血性脑卒中后晚期肌张力增高和痉挛的系统性研究结果有限。因此,本文旨在确定脑卒中7年后肌张力增高的患病率、经典的痉挛和挛性挛缩以及脑卒中7年后肌张力增高的预测因素。

在没有选择的情况下,关于缺血性脑卒中后晚期肌张力增高和痉挛的系统性研究结果有限。因此,本文旨在确定脑卒中7年后肌张力增高的患病率、经典的痉挛和挛性挛缩以及脑卒中7年后肌张力增高的预测因素。

 

在Sahlgrenska学院缺血性卒中研究中招募了年龄小于70岁的急性缺血性中风患者(n = 411)。使用斯堪的纳维亚脑卒中量表评估指数卒中时的症状。中风7年后,幸存者(n = 358)被邀请进行随访评估,其中292人同意参与,288人提供了数据。根据修正的Ashworth量表的肌张力、经典性痉挛和收缩由神经科医生评估。采用logistic回归分析研究了肌张力增加与指数性卒中和复发性卒中的特征之间的关联。

 

结果显示,99名参与者(34%)的肌张力增加:上肢94人(33%),下肢72人(25%)。51名参与者(18%)出现经典性痉挛,26名参与者(9%)出现挛缩。年龄(OR 1.03[95% CI1.00-1.06])、臂麻痹(OR 1.76[95% CI 1.40-2.2])、失语症(OR 1.68[95% CI 1.12-2.51])和面瘫(OR 2.12[95% CI 1.10-4.07])是肌张力增加的独立预测因素。

 

总之,70岁以前的缺血性脑卒中患者中,1/3的患者在7年的随访中表现出肌张力增加。其中一半的患者也有经典性痉挛。年龄、臂麻痹、失语、失语和中风时的面瘫是中风后肌张力增加的预测因素。

 

原始出处:

 

Carina U. PerssonLukas Holmegaard, et al., Increased muscle tone and contracture late after ischemic stroke. Brain Behav. 2020 Feb; 10(2): e01509.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
    2020-05-05 zhmscau
  6. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
    2020-04-08 qjddjq
  7. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
    2020-04-08 gujh
  8. [GetPortalCommentsPageByObjectIdResponse(id=1671403, encodeId=d67816e1403f9, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Dec 09 23:00:02 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893286, encodeId=d81b1893286ba, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon May 18 16:00:02 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806385, encodeId=1c14180638548, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 30 12:00:02 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947893, encodeId=7211194e89388, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Oct 05 16:00:02 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774774, encodeId=c9881e747743d, content=<a href='/topic/show?id=aa9c499213d' target=_blank style='color:#2F92EE;'>#张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49921, encryptionId=aa9c499213d, topicName=张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f38676471, createdName=zhmscau, createdTime=Tue May 05 16:00:02 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521946, encodeId=8098152194640, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540588, encodeId=7310154058870, content=<a href='/topic/show?id=fa348091883' target=_blank style='color:#2F92EE;'>#肌张力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80918, encryptionId=fa348091883, topicName=肌张力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=524213265654, createdName=gujh, createdTime=Wed Apr 08 08:00:02 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026609, encodeId=2b0c1026609e7, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon Apr 06 20:00:02 CST 2020, time=2020-04-06, status=1, ipAttribution=)]
    2020-04-06 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Stroke:绝经后妇女血浆雌二醇和睾丸激素水平与缺血性卒中的关系

由此可见,该研究的结果不支持性激素介导了绝经后妇女缺血性卒中风险的作用。需要在其他更大型的研究中进行重复验证。

Neurology:缺血性卒中后30天到90天内早期随访与再入院之间关系

由此可见,早期门诊保健科随访与减少30天的住院率有关。急性卒中入院后,早期门诊随访可能是进行干预的重要机会。

Neurology:取栓前服用 DOAC 者预后优于 VKA 者

直到2015年,发病4.5h 内给予 tPA 静脉溶栓(IVT)是急性缺血性卒中(AIS)唯一被证明有效的再灌注治疗方案。先前的抗凝治疗是 tPA 的主要禁忌症之一。抗凝治疗主要用于预防心源性脑栓塞,

Stroke:有无主动脉瓣狭窄个体缺血性卒中的发生率

与年龄和性别匹配的对照组相比,主动脉瓣狭窄患者发生缺血性卒中的风险显著增加。未来的研究将探索抗血栓治疗是否对这些个体有益。

Stroke:达比加群治疗急性非心脏栓塞性缺血性卒中的疗效

由此可见,对于急性轻度非心脏栓塞性缺血性卒中/短暂性脑缺血发作患者,达比加群具有与阿司匹林相似的HT风险。

Stroke:缺血性卒中后脑脊液减少提示脑水肿风险

近期,Stroke杂志发表研究,分析了脑脊液移位(ΔCSF)作为水肿形成的动态定量成像生物标志物的可行性。